Item Type | Name |
Academic Article
|
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer.
|
Academic Article
|
A role for curative surgery in the treatment of selected patients with metastatic breast cancer.
|
Academic Article
|
Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women
|
Academic Article
|
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged
|
Academic Article
|
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer.
|
Academic Article
|
Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy.
|
Academic Article
|
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis.
|
Academic Article
|
Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol.
|
Academic Article
|
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy.
|
Academic Article
|
Immediate breast reconstruction can impact postmastectomy irradiation.
|
Academic Article
|
Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy.
|
Academic Article
|
Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years.
|
Academic Article
|
The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.
|
Academic Article
|
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes.
|
Academic Article
|
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?
|
Academic Article
|
Prognostic value of initial clinical disease stage after achieving pathological complete response.
|
Academic Article
|
Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.
|
Academic Article
|
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
|
Academic Article
|
Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density.
|
Academic Article
|
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
|
Academic Article
|
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.
|
Academic Article
|
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.
|
Academic Article
|
Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid.
|
Academic Article
|
Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer.
|
Academic Article
|
Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma.
|
Academic Article
|
Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer.
|
Academic Article
|
Comparative analysis of sentinel lymph node operation in male and female breast cancer patients.
|
Academic Article
|
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy.
|
Concept
|
Gastrointestinal Stromal Tumors
|
Concept
|
Biliary Tract Neoplasms
|
Concept
|
Thyroid Neoplasms
|
Concept
|
Nerve Sheath Neoplasms
|
Concept
|
Genital Neoplasms, Female
|
Concept
|
Cancer Care Facilities
|
Concept
|
Early Detection of Cancer
|
Concept
|
Neuroendocrine Tumors
|
Concept
|
Jaw Neoplasms
|
Concept
|
Adrenal Cortex Neoplasms
|
Concept
|
Breast Neoplasms, Male
|
Concept
|
Mammary Neoplasms, Experimental
|
Concept
|
Neoplasms, Multiple Primary
|
Concept
|
Tumor Burden
|
Concept
|
Esophageal Neoplasms
|
Concept
|
Brain Neoplasms
|
Concept
|
Lung Neoplasms
|
Concept
|
Wilms Tumor
|
Concept
|
Neoplasms, Germ Cell and Embryonal
|
Concept
|
Tumor Suppressor Protein p53
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Neoplasm Metastasis
|
Concept
|
Genes, Tumor Suppressor
|
Concept
|
Hematologic Neoplasms
|
Concept
|
Mammary Neoplasms, Animal
|
Concept
|
Biomarkers, Tumor
|
Concept
|
Gallbladder Neoplasms
|
Concept
|
Ovarian Neoplasms
|
Concept
|
Urogenital Neoplasms
|
Concept
|
DNA, Neoplasm
|
Concept
|
Mediastinal Neoplasms
|
Concept
|
Neuroectodermal Tumors
|
Concept
|
Urinary Bladder Neoplasms
|
Concept
|
Retroperitoneal Neoplasms
|
Concept
|
Neoplasms, Second Primary
|
Concept
|
Colorectal Neoplasms
|
Concept
|
Salivary Gland Neoplasms
|
Concept
|
Cancer Vaccines
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Neoplasm Proteins
|
Concept
|
Neoplasm Staging
|
Concept
|
Tumor Escape
|
Concept
|
Kidney Neoplasms
|
Concept
|
Drug Resistance, Neoplasm
|
Concept
|
Neoplasm Transplantation
|
Concept
|
Carcinoid Tumor
|
Concept
|
Breast Neoplasms
|
Concept
|
Stomach Neoplasms
|
Concept
|
Bone Neoplasms
|
Concept
|
Tumor Stem Cell Assay
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Head and Neck Neoplasms
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
Concept
|
Bile Duct Neoplasms
|
Concept
|
Neoplasms, Glandular and Epithelial
|
Concept
|
Bone Marrow Neoplasms
|
Concept
|
Neoplasms, Hormone-Dependent
|
Concept
|
Pelvic Neoplasms
|
Concept
|
Neoplasms
|
Concept
|
Skin Neoplasms
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Neoplasm, Residual
|
Concept
|
Cell Line, Tumor
|
Concept
|
Tumor Suppressor Proteins
|
Concept
|
Gastrointestinal Neoplasms
|
Concept
|
Neoplasm Recurrence, Local
|
Concept
|
Intestinal Neoplasms
|
Concept
|
Peritoneal Neoplasms
|
Concept
|
Genes, Neoplasm
|
Concept
|
Neoplasms, Unknown Primary
|
Concept
|
RNA, Neoplasm
|
Concept
|
Liver Neoplasms
|
Concept
|
Uterine Cervical Neoplasms
|
Concept
|
Soft Tissue Neoplasms
|
Concept
|
Neoplasm Invasiveness
|
Concept
|
Testicular Neoplasms
|
Concept
|
Endometrial Neoplasms
|
Academic Article
|
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.
|
Academic Article
|
Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy.
|
Academic Article
|
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.
|
Academic Article
|
Expression of c-kit proto-oncogene product in breast tissue.
|
Academic Article
|
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer.
|
Academic Article
|
RET fusion as a novel driver of medullary thyroid carcinoma.
|
Academic Article
|
Functional consequence of the MET-T1010I polymorphism in breast cancer.
|
Academic Article
|
Prevention of radiation enteritis in children, using a pelvic mesh sling.
|
Academic Article
|
HER2/neu in the management of invasive breast cancer.
|
Academic Article
|
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas.
|
Academic Article
|
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
|
Academic Article
|
Histologic localization of sentinel lymph node metastases in breast cancer.
|
Academic Article
|
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.
|
Academic Article
|
Determinants of rapamycin sensitivity in breast cancer cells.
|
Academic Article
|
Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge.
|
Academic Article
|
Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma.
|
Academic Article
|
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
|
Academic Article
|
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.
|
Academic Article
|
Paget's disease of the breast: there is a role for breast-conserving therapy.
|
Academic Article
|
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
|
Academic Article
|
Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy.
|
Academic Article
|
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
|
Academic Article
|
Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center.
|
Academic Article
|
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma.
|
Academic Article
|
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective?
|
Academic Article
|
Trends for inflammatory breast cancer: is survival improving?
|
Academic Article
|
Commonly cited website quality criteria are not effective at identifying inaccurate online information about breast cancer.
|
Academic Article
|
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.
|
Academic Article
|
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.
|
Academic Article
|
Translation initiation factor 4E (eIF4E): prognostic marker and potential therapeutic target.
|
Academic Article
|
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.
|
Academic Article
|
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
|
Academic Article
|
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.
|
Academic Article
|
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.
|
Academic Article
|
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
|
Academic Article
|
Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer.
|
Academic Article
|
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
|
Academic Article
|
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
|
Academic Article
|
Biology, treatment, and outcome in very young and older women with DCIS.
|
Academic Article
|
Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
|
Academic Article
|
Genotype in BRCA-associated breast cancers.
|
Academic Article
|
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.
|
Academic Article
|
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes.
|
Academic Article
|
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
|
Academic Article
|
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer.
|
Academic Article
|
Ductal carcinoma-in-situ: long-term results of breast-conserving therapy.
|
Academic Article
|
Expression profile of tyrosine kinases in breast cancer.
|
Academic Article
|
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites.
|
Academic Article
|
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy.
|
Academic Article
|
Radiofrequency ablation of early-stage invasive breast tumors: an overview.
|
Academic Article
|
Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences.
|
Academic Article
|
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
|
Academic Article
|
Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery.
|
Academic Article
|
Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma.
|
Academic Article
|
Molecular therapeutics: promise and challenges.
|
Academic Article
|
Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields.
|
Academic Article
|
Expression of sigma 1 receptor in human breast cancer.
|
Academic Article
|
Breast conservation after neoadjuvant chemotherapy.
|
Academic Article
|
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
|
Academic Article
|
Improving local control with breast-conserving therapy: a 27-year single-institution experience.
|
Academic Article
|
Searching for cancer-related information online: unintended retrieval of complementary and alternative medicine information.
|
Academic Article
|
Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
|
Academic Article
|
Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways.
|
Academic Article
|
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
|
Academic Article
|
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
|
Academic Article
|
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
|
Academic Article
|
Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.
|
Academic Article
|
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.
|
Academic Article
|
Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
|
Academic Article
|
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery.
|
Academic Article
|
Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival.
|
Academic Article
|
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection.
|
Academic Article
|
Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy.
|
Academic Article
|
Currency of online breast cancer information.
|
Academic Article
|
Development of new cancers in patients with DCIS: the M.D. Anderson experience.
|
Academic Article
|
Prognostic significance of HER-2 status in women with inflammatory breast cancer.
|
Academic Article
|
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
|
Academic Article
|
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer.
|
Academic Article
|
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling.
|
Academic Article
|
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.
|
Academic Article
|
Building a predictive breast cancer risk model.
|
Academic Article
|
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
|
Academic Article
|
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients.
|
Academic Article
|
Regulation and localization of ribosomal protein S6 kinase 1 isoforms.
|
Academic Article
|
High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.
|
Academic Article
|
The impact of pregnancy on breast cancer outcomes in women
|
Academic Article
|
Targeting the mTOR signaling network for cancer therapy.
|
Academic Article
|
Rak functions as a tumor suppressor by regulating PTEN protein stability and function.
|
Academic Article
|
Intra-individual comparison of lymphatic drainage patterns using subareolar and peritumoral isotope injection for breast cancer.
|
Academic Article
|
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
|
Academic Article
|
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival.
|
Academic Article
|
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients.
|
Academic Article
|
Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment.
|
Academic Article
|
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
|
Academic Article
|
ASBrS and ASO: a new partnership begins.
|
Academic Article
|
Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.
|
Academic Article
|
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer.
|
Academic Article
|
Sentinel lymph node dissection is technically feasible in older breast cancer patients.
|
Academic Article
|
A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes.
|
Academic Article
|
The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo.
|
Academic Article
|
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial.
|
Academic Article
|
HER2 studies look promising.
|
Academic Article
|
Quantitative proteomic analysis in breast cancer.
|
Academic Article
|
Nanomedicine in cancer therapy: innovative trends and prospects.
|
Academic Article
|
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
|
Academic Article
|
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients.
|
Academic Article
|
Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.
|
Academic Article
|
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers.
|
Academic Article
|
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
|
Academic Article
|
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
|
Academic Article
|
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
|
Academic Article
|
Earlier age of onset of BRCA mutation-related cancers in subsequent generations.
|
Academic Article
|
cMET and phospho-cMET protein levels in breast cancers and survival outcomes.
|
Academic Article
|
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.
|
Academic Article
|
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
|
Academic Article
|
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
|
Academic Article
|
Multifocality and multicentricity in breast cancer and survival outcomes.
|
Academic Article
|
Overcoming implementation challenges of personalized cancer therapy.
|
Academic Article
|
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
|
Academic Article
|
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population.
|
Academic Article
|
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients.
|
Academic Article
|
Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation.
|
Academic Article
|
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.
|
Academic Article
|
Building a personalized medicine infrastructure at a major cancer center.
|
Academic Article
|
Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer.
|
Academic Article
|
Adenovirus 5 early region 1A does not induce expression of the ewing sarcoma fusion product EWS-FLI1 in breast and ovarian cancer cell lines.
|
Academic Article
|
Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience.
|
Academic Article
|
Long-term complications associated with breast-conservation surgery and radiotherapy.
|
Academic Article
|
Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge.
|
Academic Article
|
Chest wall recurrence after mastectomy does not always portend a dismal outcome.
|
Academic Article
|
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
|
Academic Article
|
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
|
Academic Article
|
Cancer-related complementary and alternative medicine online: factors affecting information retrieval.
|
Academic Article
|
Serum proteomics for BRCA1-associated breast cancer.
|
Academic Article
|
Mammalian target of rapamycin.
|
Academic Article
|
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.
|
Academic Article
|
Determinants of mastectomy in breast conservation therapy candidates.
|
Academic Article
|
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy.
|
Academic Article
|
Accuracy and self correction of information received from an internet breast cancer list: content analysis.
|
Academic Article
|
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer.
|
Academic Article
|
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.
|
Academic Article
|
Selective use of sentinel lymph node surgery during prophylactic mastectomy.
|
Academic Article
|
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
|
Academic Article
|
Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
|
Academic Article
|
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis.
|
Academic Article
|
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
|
Academic Article
|
Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hit.
|
Academic Article
|
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy.
|
Academic Article
|
Rapamycin regulates the phosphorylation of rictor.
|
Academic Article
|
Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy.
|
Academic Article
|
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.
|
Academic Article
|
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.
|
Academic Article
|
RNA-binding specificity of Y-box protein 1.
|
Academic Article
|
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy.
|
Academic Article
|
A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer.
|
Academic Article
|
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
|
Academic Article
|
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
|
Academic Article
|
Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.
|
Academic Article
|
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery.
|
Academic Article
|
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
|
Academic Article
|
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.
|
Academic Article
|
False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden.
|
Academic Article
|
The rapamycin-regulated gene expression signature determines prognosis for breast cancer.
|
Academic Article
|
Metformin: a therapeutic opportunity in breast cancer.
|
Academic Article
|
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.
|
Academic Article
|
A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients.
|
Academic Article
|
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
|
Academic Article
|
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer.
|
Academic Article
|
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis.
|
Academic Article
|
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning.
|
Academic Article
|
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
|
Academic Article
|
Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance.
|
Academic Article
|
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.
|
Academic Article
|
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.
|
Academic Article
|
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.
|
Academic Article
|
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
|
Academic Article
|
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.
|
Academic Article
|
Molecular-targeted nanotherapies in cancer: enabling treatment specificity.
|
Academic Article
|
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node.
|
Academic Article
|
Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.
|
Academic Article
|
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.
|
Academic Article
|
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
|
Academic Article
|
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns.
|
Academic Article
|
Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment.
|
Academic Article
|
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
|
Academic Article
|
Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy.
|
Academic Article
|
Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq.
|
Academic Article
|
Two birds with one stone: octreotide treatment for acromegaly and breast cancer.
|
Academic Article
|
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
|
Academic Article
|
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?
|
Academic Article
|
Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients.
|
Academic Article
|
Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
|
Academic Article
|
Reply to letter: "Waiting time for breast cancer treatment".
|
Academic Article
|
CanDrA: cancer-specific driver missense mutation annotation with optimized features.
|
Academic Article
|
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
|
Academic Article
|
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.
|
Academic Article
|
Breast-conservation therapy in early-stage breast cancer patients with a positive family history.
|
Academic Article
|
Translation initiation in cancer: a novel target for therapy.
|
Academic Article
|
Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study.
|
Academic Article
|
Breast conservation in breast cancer: surgical and adjuvant considerations.
|
Academic Article
|
Contralateral prophylactic mastectomy. Predictors of significant histologic findings.
|
Academic Article
|
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
|
Academic Article
|
Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.
|
Academic Article
|
Does blue dye contribute to success of sentinel node mapping for breast cancer?
|
Academic Article
|
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
|
Academic Article
|
PurityEst: estimating purity of human tumor samples using next-generation sequencing data.
|
Academic Article
|
The impact of tumor heterogeneity on patient treatment decisions.
|
Academic Article
|
Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy.
|
Academic Article
|
Accelerated approval and breakthrough therapy designation: oncology drug development on speed?
|
Academic Article
|
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
|
Academic Article
|
Breast cancer multifocality and multicentricity and locoregional recurrence.
|
Academic Article
|
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.
|
Academic Article
|
Attitudes regarding privacy of genomic information in personalized cancer therapy.
|
Academic Article
|
Treatment and outcome of patients with intracystic papillary carcinoma of the breast.
|
Academic Article
|
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy.
|
Academic Article
|
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
|
Academic Article
|
Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
|
Academic Article
|
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
|
Academic Article
|
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy.
|
Academic Article
|
Triple-negative breast cancer is not a contraindication for breast conservation.
|
Academic Article
|
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer.
|
Academic Article
|
Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival.
|
Academic Article
|
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
|
Academic Article
|
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.
|
Academic Article
|
PD-L1 expression in triple-negative breast cancer.
|
Academic Article
|
Clonal evolution in breast cancer revealed by single nucleus genome sequencing.
|
Academic Article
|
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.
|
Academic Article
|
Which threshold for ER positivity? a retrospective study based on 9639 patients.
|
Academic Article
|
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.
|
Academic Article
|
Concordance of genomic alterations between primary and recurrent breast cancer.
|
Academic Article
|
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?.
|
Academic Article
|
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
|
Academic Article
|
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
|
Academic Article
|
A pan-cancer proteomic perspective on The Cancer Genome Atlas.
|
Academic Article
|
Influence of biospecimen variables on proteomic biomarkers in breast cancer.
|
Academic Article
|
The role of surgeons in building a personalized medicine program.
|
Academic Article
|
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
|
Academic Article
|
Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
|
Academic Article
|
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
|
Academic Article
|
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
|
Academic Article
|
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
|
Academic Article
|
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
|
Academic Article
|
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.
|
Academic Article
|
Attitudes toward molecular testing for personalized cancer therapy.
|
Academic Article
|
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
|
Academic Article
|
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
|
Academic Article
|
Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.
|
Academic Article
|
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
|
Academic Article
|
Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.
|
Academic Article
|
Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.
|
Academic Article
|
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
|
Academic Article
|
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.
|
Academic Article
|
Clinical actionability enhanced through deep targeted sequencing of solid tumors.
|
Academic Article
|
Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas.
|
Academic Article
|
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
|
Academic Article
|
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
|
Academic Article
|
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
|
Academic Article
|
Adapting a natural language processing tool to facilitate clinical trial curation for personalized cancer therapy.
|
Academic Article
|
Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations.
|
Academic Article
|
Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.
|
Academic Article
|
A decision support framework for genomically informed investigational cancer therapy.
|
Academic Article
|
Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
|
Academic Article
|
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
|
Academic Article
|
Epithelial to mesenchymal transition is associated with rapamycin resistance.
|
Academic Article
|
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
|
Academic Article
|
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
|
Academic Article
|
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
|
Academic Article
|
Clinical next generation sequencing to identify actionable aberrations in a phase I program.
|
Academic Article
|
Whole Genome Sequencing in Cancer Clinics.
|
Academic Article
|
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.
|
Academic Article
|
A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer.
|
Academic Article
|
Hepatocellular carcinoma: Where there is unmet need.
|
Academic Article
|
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
|
Academic Article
|
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
|
Academic Article
|
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
|
Academic Article
|
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.
|
Academic Article
|
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.
|
Academic Article
|
TransVar: a multilevel variant annotator for precision genomics.
|
Academic Article
|
Targeting translation initiation in breast cancer.
|
Academic Article
|
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
|
Academic Article
|
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
|
Academic Article
|
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
|
Academic Article
|
Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience.
|
Academic Article
|
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
|
Academic Article
|
Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
|
Academic Article
|
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience.
|
Academic Article
|
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
|
Academic Article
|
Patient-derived xenograft (PDX) models in basic and translational breast cancer research
|
Academic Article
|
Survival of patients with metastatic leiomyosarcoma
|
Academic Article
|
Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation
|
Academic Article
|
Currency of online breast cancer information
|
Academic Article
|
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer
|
Academic Article
|
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types
|
Academic Article
|
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors
|
Academic Article
|
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
|
Academic Article
|
Locally advanced breast cancer
|
Academic Article
|
Predictors of systemic recurrence and impact of local failure among early stage breast cancer patients treated with breast conserving therapy
|
Academic Article
|
MET amplification in metastatic colorectal cancer
|
Academic Article
|
High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer
|
Academic Article
|
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy
|
Academic Article
|
Breast cancer metastatic to abdomen and pelvis
|
Academic Article
|
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer
|
Academic Article
|
A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer
|
Academic Article
|
Phase i study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors
|
Academic Article
|
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
|
Academic Article
|
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
|
Academic Article
|
Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]
|
Academic Article
|
Ability to generate patient-derived Breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes
|
Academic Article
|
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion
|
Academic Article
|
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials
|
Academic Article
|
Ribociclib plus letrozole in early breast cancer
|
Academic Article
|
MET nucleotide variations and amplification in advanced ovarian cancer
|
Academic Article
|
mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer
|
Academic Article
|
BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system
|
Academic Article
|
Patient knowledge and information-seeking about personalized cancer therapy
|
Academic Article
|
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
|
Academic Article
|
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
|
Academic Article
|
Erratum
|
Academic Article
|
Biliary cancer
|
Academic Article
|
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
|
Academic Article
|
Erratum
|
Academic Article
|
Clinical outcomes based on multigene profiling in metastatic breast cancer patients
|
Academic Article
|
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer
|
Academic Article
|
Quality and accuracy of breast cancer information on the World Wide Web
|
Academic Article
|
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
|
Academic Article
|
Risk of ipsilateral and contralateral cancer in BRCA mutation carriers with breast cancer
|
Academic Article
|
Growth inhibition of breast cancer cells by celecoxib
|
Academic Article
|
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer
|
Academic Article
|
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit
|
Academic Article
|
Phase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer
|
Academic Article
|
Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov
|
Academic Article
|
Erratum
|
Academic Article
|
High intratumoral stromal content defines reactive breast cancer as a low-risk breast cancer subtype
|
Academic Article
|
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
|
Academic Article
|
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
|
Academic Article
|
Systematic Functional Annotation of Somatic Mutations in Cancer.
|
Academic Article
|
Pathogenic Germline Variants in 10,389 Adult Cancers.
|
Academic Article
|
High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study.
|
Academic Article
|
Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.
|
Academic Article
|
Reply to M.P. Decatris et al.
|
Academic Article
|
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
|
Academic Article
|
Patient knowledge and information-seeking about personalized cancer therapy.
|
Academic Article
|
Extracting genetic alteration information for personalized cancer therapy from ClinicalTrials.gov.
|
Academic Article
|
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
|
Academic Article
|
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report.
|
Academic Article
|
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer.
|
Academic Article
|
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
|
Academic Article
|
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types.
|
Academic Article
|
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.
|
Academic Article
|
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
|
Academic Article
|
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.
|
Academic Article
|
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.
|
Academic Article
|
Automated identification of molecular effects of drugs (AIMED).
|
Academic Article
|
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.
|
Academic Article
|
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
|
Academic Article
|
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
|
Academic Article
|
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.
|
Academic Article
|
Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
|
Academic Article
|
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.
|
Academic Article
|
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
|
Academic Article
|
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
|
Academic Article
|
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
|
Academic Article
|
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
|
Academic Article
|
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.
|
Academic Article
|
ALK: a tyrosine kinase target for cancer therapy.
|
Academic Article
|
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.
|
Academic Article
|
Biliary cancer: Utility of next-generation sequencing for clinical management.
|
Academic Article
|
Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.
|
Academic Article
|
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
|
Academic Article
|
Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual.
|
Academic Article
|
Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.
|
Academic Article
|
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
|
Academic Article
|
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
|
Academic Article
|
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
|
Academic Article
|
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.
|
Academic Article
|
Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.
|
Academic Article
|
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
|
Academic Article
|
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
|
Academic Article
|
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer.
|
Academic Article
|
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
|
Academic Article
|
First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients.
|
Academic Article
|
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
|
Academic Article
|
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
|
Academic Article
|
Targeting TRK family proteins in cancer.
|
Academic Article
|
Identification of frequent somatic mutations in inflammatory breast cancer.
|
Academic Article
|
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
|
Academic Article
|
Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer.
|
Academic Article
|
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.
|
Academic Article
|
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
|
Academic Article
|
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors.
|
Academic Article
|
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.
|
Academic Article
|
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.
|
Academic Article
|
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
|
Academic Article
|
"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.
|
Academic Article
|
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
|
Academic Article
|
Physician interpretation of genomic test results and treatment selection.
|
Academic Article
|
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.
|
Academic Article
|
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.
|
Academic Article
|
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.
|
Academic Article
|
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
|
Academic Article
|
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
|
Academic Article
|
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
|
Academic Article
|
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing.
|
Academic Article
|
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.
|
Academic Article
|
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
|
Academic Article
|
Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
|
Academic Article
|
Cancer driver mutation prediction through Bayesian integration of multi-omic data.
|
Academic Article
|
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
|
Academic Article
|
Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
|
Academic Article
|
Reply to J.J. Tao et al.
|
Academic Article
|
Targeting the PI3K pathway in cancer: are we making headway?
|
Academic Article
|
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
|
Academic Article
|
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.
|
Academic Article
|
Personalized cancer therapy-leveraging a knowledge base for clinical decision-making.
|
Academic Article
|
Precision Oncology Decision Support: Current Approaches and Strategies for the Future.
|
Academic Article
|
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
|
Academic Article
|
Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.
|
Academic Article
|
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
|
Academic Article
|
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer.
|
Academic Article
|
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
|
Academic Article
|
Challenges with biomarkers in cancer drug discovery and development.
|
Academic Article
|
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
|
Academic Article
|
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
|
Academic Article
|
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
|
Academic Article
|
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.
|
Academic Article
|
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.
|
Academic Article
|
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
|
Academic Article
|
Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
|
Academic Article
|
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.
|
Academic Article
|
Molecular determinants of post-mastectomy breast cancer recurrence.
|
Academic Article
|
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
|
Academic Article
|
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
|
Academic Article
|
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
|
Academic Article
|
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
|
Academic Article
|
Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.
|
Academic Article
|
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
|
Academic Article
|
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients.
|
Academic Article
|
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
|
Academic Article
|
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
|
Academic Article
|
Clinical and molecular characterization of early-onset colorectal cancer.
|
Academic Article
|
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
|
Academic Article
|
Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.
|
Academic Article
|
Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
|
Academic Article
|
Prospective Clinical Sequencing of Adult Glioma.
|
Academic Article
|
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.
|
Academic Article
|
MK-2206 window of opportunity study in breast cancer.
|
Academic Article
|
FGFR1? is a driver isoform of FGFR1 alternative splicing in breast cancer cells.
|
Academic Article
|
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
|
Academic Article
|
Integrated transcriptomic-genomic tool Texomer profiles cancer tissues.
|
Academic Article
|
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
|
Concept
|
Circulating Tumor DNA
|
Concept
|
Inflammatory Breast Neoplasms
|
Concept
|
Tumor Microenvironment
|
Concept
|
Neoplasm Grading
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
Concept
|
Triple Negative Breast Neoplasms
|
Concept
|
Response Evaluation Criteria in Solid Tumors
|
Academic Article
|
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
|
Academic Article
|
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
|
Academic Article
|
OCTANE: Oncology Clinical Trial Annotation Engine.
|
Academic Article
|
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
|
Academic Article
|
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.
|
Academic Article
|
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
|
Academic Article
|
Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141].
|
Academic Article
|
Next-generation sequencing for the general cancer patient.
|
Academic Article
|
TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.
|
Academic Article
|
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
|
Academic Article
|
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
|
Academic Article
|
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.
|
Academic Article
|
Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors.
|
Academic Article
|
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
|
Academic Article
|
Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib.
|
Academic Article
|
Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.
|
Academic Article
|
Targeting AKT for cancer therapy.
|
Academic Article
|
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
|
Academic Article
|
Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation.
|
Academic Article
|
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
|
Academic Article
|
Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study.
|
Academic Article
|
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.
|
Academic Article
|
Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.
|
Academic Article
|
Correction: FGFR1? is a driver isoform of FGFR1 alternative splicing in breast cancer cells.
|
Academic Article
|
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
|
Academic Article
|
Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.
|
Academic Article
|
Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.
|
Academic Article
|
Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers.
|
Academic Article
|
State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
|
Academic Article
|
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
|
Academic Article
|
Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin-Stained Sections of Core-Needle Biopsy Specimens.
|
Academic Article
|
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
|
Academic Article
|
Phase 2 study of pembrolizumab in patients with advanced rare cancers.
|
Academic Article
|
Targeting PI3K? alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.
|
Academic Article
|
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
|
Academic Article
|
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.
|
Academic Article
|
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
|
Academic Article
|
COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission.
|
Academic Article
|
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
|
Academic Article
|
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers.
|
Academic Article
|
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
|
Academic Article
|
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
|
Academic Article
|
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer.
|
Academic Article
|
Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors.
|
Academic Article
|
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
|
Academic Article
|
Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.
|
Academic Article
|
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies.
|
Academic Article
|
Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers.
|
Academic Article
|
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study.
|
Academic Article
|
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
|
Academic Article
|
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
|
Academic Article
|
TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer.
|
Academic Article
|
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
|
Academic Article
|
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
|
Academic Article
|
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors.
|
Academic Article
|
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
|
Academic Article
|
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
|
Academic Article
|
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
|
Academic Article
|
Enhancing anti-tumour efficacy with immunotherapy combinations.
|
Academic Article
|
Strategies for improving the management of immune-related adverse events.
|
Academic Article
|
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.
|
Academic Article
|
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
|
Academic Article
|
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
|
Academic Article
|
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
|
Academic Article
|
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.
|
Academic Article
|
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.
|
Academic Article
|
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
|
Academic Article
|
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
|
Academic Article
|
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.
|
Academic Article
|
Next generation sequencing for biliary tract cancers.
|
Academic Article
|
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
|
Academic Article
|
Associations between the gut microbiome and fatigue in cancer patients.
|
Academic Article
|
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
|
Academic Article
|
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.
|
Academic Article
|
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
|
Academic Article
|
Breast tumours maintain a reservoir of subclonal diversity during expansion.
|
Academic Article
|
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
|
Academic Article
|
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
|
Academic Article
|
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
|
Academic Article
|
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
|
Academic Article
|
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
|
Academic Article
|
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
|
Academic Article
|
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
|
Academic Article
|
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase?II Trial.
|
Academic Article
|
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy.
|
Academic Article
|
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
|
Academic Article
|
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
|
Academic Article
|
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
|
Academic Article
|
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
|
Academic Article
|
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
|
Academic Article
|
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.
|
Academic Article
|
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
|
Academic Article
|
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.
|
Academic Article
|
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
|
Academic Article
|
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
|
Academic Article
|
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
|
Academic Article
|
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
|
Academic Article
|
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
|
Academic Article
|
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
|
Academic Article
|
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
|
Academic Article
|
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
|
Academic Article
|
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.
|
Academic Article
|
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.
|
Academic Article
|
Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
|
Academic Article
|
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
|
Academic Article
|
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
|
Academic Article
|
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.
|
Academic Article
|
Natural Language Processing-Assisted Literature Retrieval and Analysis for Combination Therapy in Cancer.
|
Academic Article
|
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
|
Academic Article
|
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
|
Academic Article
|
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.
|
Academic Article
|
Prospecting whole cancer genomes.
|
Academic Article
|
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
|
Academic Article
|
Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.
|
Academic Article
|
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.
|
Academic Article
|
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
|
Academic Article
|
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
|
Academic Article
|
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
|
Academic Article
|
Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
|
Academic Article
|
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection.
|
Academic Article
|
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.
|
Academic Article
|
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
|
Academic Article
|
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
|
Academic Article
|
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial.
|
Academic Article
|
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens.
|
Academic Article
|
Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.
|
Academic Article
|
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.
|
Academic Article
|
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.
|
Academic Article
|
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.
|
Academic Article
|
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).
|
Academic Article
|
A path to translation: How 3D patient tumor avatars enable next generation precision oncology.
|
Academic Article
|
Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
|
Academic Article
|
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
|
Academic Article
|
Antibody-drug conjugates in lung cancer: dawn of a new era?
|
Academic Article
|
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
|
Academic Article
|
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.
|
Academic Article
|
Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer.
|
Academic Article
|
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience.
|
Academic Article
|
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
|
Academic Article
|
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.
|
Academic Article
|
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
|
Academic Article
|
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
|
Academic Article
|
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
|
Academic Article
|
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
|
Academic Article
|
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials.
|
Academic Article
|
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
|
Academic Article
|
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.
|
Academic Article
|
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
|
Academic Article
|
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
|
Academic Article
|
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
|
Academic Article
|
Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing.
|
Academic Article
|
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
|
Academic Article
|
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
|
Academic Article
|
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
|
Academic Article
|
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
|
Academic Article
|
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
|
Academic Article
|
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
|
Academic Article
|
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
|
Academic Article
|
Discordance of HER2 Expression and/or Amplification on Repeat Testing.
|
Academic Article
|
Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
|
Academic Article
|
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
|
Academic Article
|
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
|
Academic Article
|
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data.
|
Academic Article
|
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
|
Academic Article
|
Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study.
|
Academic Article
|
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
|
Academic Article
|
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors.
|
Academic Article
|
HER2-low expression in patients with advanced or metastatic solid tumors.
|
Academic Article
|
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
|
Academic Article
|
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
|
Academic Article
|
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
|
Academic Article
|
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.
|
Academic Article
|
The New NCI Precision Medicine Trials.
|
Academic Article
|
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
|
Academic Article
|
Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
|
Academic Article
|
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
|
Academic Article
|
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
|
Academic Article
|
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
|
Academic Article
|
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
|
Academic Article
|
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
|
Academic Article
|
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
|
Academic Article
|
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
Academic Article
|
Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
|
Academic Article
|
Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
|
Academic Article
|
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
|
Academic Article
|
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
|
Academic Article
|
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
|
Academic Article
|
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
|
Academic Article
|
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.
|
Academic Article
|
Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1-4 Inhibitor: Pooled Safety Analysis of 469 Patients.
|
Academic Article
|
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
|
Academic Article
|
Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
|
Academic Article
|
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
|
Academic Article
|
Ataxia-Telangiectasia Mutated (ATM) loss of function displays variant and tissue-specific differences across tumor types.
|
Academic Article
|
Precision Oncology in Hepatopancreatobiliary Cancer Surgery.
|
Academic Article
|
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
|
Academic Article
|
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
|
Academic Article
|
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
|